结直肠癌患者的肿瘤相关胰蛋白酶抑制剂（TATI）。与癌胚抗原（CEA）的关键比较。

Tumor-associated trypsin inhibitor (TATI) in patients with colorectal carcinoma. A critical comparison with CEA.

作者信息

Catarino M, Conde R

机构信息

Faculty of Pharmacy, University of Lisbon, Portugal.

出版信息

Scand J Clin Lab Invest Suppl. 1991;207:43-6. doi: 10.3109/00365519109104625.

DOI:10.3109/00365519109104625

PMID:1780689

Abstract

We have evaluated the clinical utility of tumor-associated trypsin inhibitor (TATI) in colorectal cancer and compared it with carcinoembryonic antigen (CEA), the classical marker for this disease. We measured the serum levels of these markers in 53 patients with colorectal carcinoma before and after surgery. CEA was found to have greater sensitivity than TATI in this disease. The TATI concentrations did not correlate as well as CEA with the presence or absence of metastasis and with the course of the disease after surgery. The use of TATI together with CEA for detection or follow up of colorectal cancer does not seem to be useful because a significant increase of positivity is not obtained as compared with determination of CEA alone.

摘要

我们评估了肿瘤相关胰蛋白酶抑制剂（TATI）在结直肠癌中的临床应用价值，并将其与该疾病的经典标志物癌胚抗原（CEA）进行了比较。我们检测了53例结直肠癌患者手术前后这两种标志物的血清水平。结果发现，在该疾病中CEA比TATI具有更高的敏感性。TATI浓度与转移的有无以及手术后疾病的进程之间的相关性不如CEA。将TATI与CEA联合用于结直肠癌的检测或随访似乎并无用处，因为与单独检测CEA相比，阳性率并未显著提高。